Zinc and di-iodohydroxyquinoline therapy in acrodermatitis enteropathica.
A 25-year-old patient with acrodermatitis enteropathica who had been treated with di-iodohydroxyquinoline for 20 years was changed to zinc sulphate therapy and studied under full metabolic balance control for zinc, calcium, magnesium, and inorganic phosphorus. The results obtained indicate that there is only a small overall deficit of body zinc stores in this disease and that the function of di-iodohydroxyquinoline is to increase the amount of zinc absorbed and retained by the body.
D000169:Acrodermatitis / Q000188:drug therapy* / Q000378:metabolism; D000328:Adult; D003276:Contraceptives, Oral / Q000009:adverse effects; D005260:Female; D006801:Humans; D004103:Iodoquinol / Q000627:therapeutic use*; D015032:Zinc / Q000172:deficiency* / Q000627:therapeutic use
D003276:Contraceptives, Oral; D004103:Iodoquinol; D015032:Zinc